Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
Barbara RossettiRoberta GagliardiniGenny MeiniGaetana SterrantinoVincenzo ColangeliMaria Carla ReAlessandra LatiniManuela ColafigliFrancesca VignaleStefano RusconiValeria MicheliAntonio Di BiagioGiancarlo OrofinoValeria GhisettiAlessandra FantauzziVincenzo VulloPierfrancesco GrimaDaniela FrancisciClaudio MastroianniAndrea AntinoriMichele TrezziLucia LisiPierluigi NavarraBenedetta CanovariAntonella D'Arminio MonforteSilvia LamonicaAlessandro D'AvinoMaurizio ZazziSimona Di GiambenedettoAndrea De Lucanull nullPublished in: PloS one (2017)
Switching to maraviroc with darunavir/ritonavir qd in virologically suppressed patients was associated with improved tolerability but was virologically inferior to 3-drug therapy.
Keyphrases
- antiretroviral therapy
- hiv infected patients
- hiv infected
- hiv positive
- human immunodeficiency virus
- hiv aids
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- randomized controlled trial
- prognostic factors
- clinical trial
- bone marrow
- double blind
- study protocol
- drug induced
- hepatitis c virus
- electronic health record